Results 271 to 280 of about 61,873 (295)

Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial

Lancet Respiratory Medicine,the, 2020
Carmen Casaulta, Samuel A Collins, Claire Hogg   +2 more
exaly  

Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts

Annals of Neurology, 2018
Alberto Espay, Francesca Morgante, Aristide Merola   +2 more
exaly  

Mortality and Tardive Dyskinesia

American Journal of Psychiatry, 1979
L T, Kucharski, J W, Smith, D D, Dunn
openaire   +2 more sources

Tardive dyskinesia (syndrome): Current concept and modern approaches to its management

Psychiatry and Clinical Neurosciences, 2015
Paul P. Lerner, C. Miodownik, V. Lerner
semanticscholar   +1 more source

X-linked primary ciliary dyskinesia due to mutations in the cytoplasmic axonemal dynein assembly factor PIH1D3

Nature Communications, 2017
Amelia Shoemark, Marie Legendre, Cara K Vaughan   +2 more
exaly  

Tardive Dyskinesia and Tardive Dystonia With Second-Generation Antipsychotics in Non-Elderly Schizophrenic Patients Unexposed to First-Generation Antipsychotics: A Cross-Sectional and Retrospective Study

Journal of Clinical Psychopharmacology, 2015
Seunghyong Ryu, J. Yoo, Joo Hyun Kim, J. Choi, J. Baek, Kyooseob Ha, J. Kwon, K. Hong   +7 more
semanticscholar   +1 more source

Primary Ciliary Dyskinesia

American Journal of Respiratory and Critical Care Medicine, 2004
Maimoona A Zariwala, Michael R Knowles
exaly  

Tardive Dyskinesia

Clinical Neuropharmacology, 1986
C M, Tanner, H L, Klawans
openaire   +2 more sources

Valbenazine granted breakthrough drug status for treating tardive dyskinesia

Expert Opinion on Investigational Drugs, 2015
T. Müller
semanticscholar   +1 more source

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats

Brain, 2007
Manolo Carta, Deniz Kirik
exaly